Celularity to present in vivo data from T-cell therapy platform at AACR

Celularity announced that it will present in vivo data from its T-cell therapy platform at this year’s AACR Annual Meeting. These data, which “highlight the platform’s robust anti-tumor activity against gastric cancer,” will be presented on April 9, the company stated. “These data demonstrate the promise and potential of combining Celularity’s cell therapy assets with currently available therapies to address difficult-to-treat cancers. With this study, we are also advancing our pipeline to address aging-related healthcare challenges, including cancer. This work highlights the deep expertise and capabilities in cell therapy resident at Celularity, employing our platform of placental-derived cell products and our ability to engineer those cells in our state-of-the-art manufacturing facility,” added Dr. Robert Hariri, Celularity’s CEO and Founder.